Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 9/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.51 |
| ▸ | RORC | P51449 | 10/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779550 | 0.84 | PDCD1 (0.47) | PDCD1CD274 | |
| SCHEMBL19785493 | 0.83 | PDCD1 (0.52) | PDCD1CD274IRAK4 | |
| SCHEMBL19780011 | 0.83 | CD274 (0.54) | PDCD1CD274 | |
| SCHEMBL29893930 | 0.83 | CD274 (0.54) | PDCD1CD274 | |
| SCHEMBL19779671 | 0.83 | RORC (0.39) | PDCD1CD274RORCIRAK4 | |
| SCHEMBL19779688 | 0.83 | RORC (0.40) | PDCD1CD274RORCIRAK4 | |
| SCHEMBL19779868 | 0.80 | RORC (0.39) | PDCD1CD274RORCIRAK4 | |
| SCHEMBL29893922 | 0.80 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL25909537 | 0.80 | PDCD1 (0.53) | PDCD1CD274 | |
| SCHEMBL19779434 | 0.80 | PDCD1 (0.49) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | claimed |
| EP-3484866-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-09-07 | — | — | EP | claimed |
| US-20180016260-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-01-18 | — | — | US | claimed |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3484866-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20210115025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-20210115025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-20200283423-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20200283423-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20180016260-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-01-18 | — | — | US | disclosed |
| US-20180016260-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283423-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885RORC 31/4885 |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885RORC 31/4885 |
| US-20210115025-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885RORC 31/4885 |
| US-20180016260-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885RORC 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.